The A3 adenosine receptor:: An enigmatic player in cell biology

被引:173
作者
Gessi, Stefania [1 ,2 ]
Merighi, Stefania [1 ,2 ]
Varani, Katia [1 ,2 ]
Leung, Edward [3 ]
Mac Lennan, Stephen [3 ]
Borea, Pier Andrea [1 ,2 ]
机构
[1] Dept Clin & Expt Med, Pharmacol Unit, Ferrara, Italy
[2] Interdisciplinary Ctr Study Inflammat, Ferrara, Italy
[3] King Pharmaceut Inc, Cary, NC USA
关键词
adenosine A(3) receptor; gene and tissue localization; ischemic conditions; inflammation; cancer;
D O I
10.1016/j.pharmthera.2007.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine is a primordial signaling molecule present in every cell of the human body that mediates its physiological functions by interacting with 4 subtypes of G-protein-coupled receptors, termed A(1), A(2A), A(2B) and A(3). The A(3) subtype is perhaps the most enigmatic among adenosine receptors since, although several studies have been performed in the years to elucidate its physiological function, it still presents in several cases a double nature in different pathophysiological conditions. The 2 personalities of A(3) often come into direct conflict, e.g., in ischemia, inflammation and cancer, rendering this receptor as a single entity behaving in 2 different ways. This review focuses on the most relevant aspects of A(3) adenosine subtype activation and summarizes the pharmacological evidence as the basis of the dichotomy of this receptor in different therapeutic fields. Although much is still to be learned about the function of the A(3) receptor and in spite of its duality, at the present time it can be speculated that A(3) receptor selective ligands might show utility in the treatment of ischemic conditions, glaucoma, asthma, arthritis, cancer and other disorders in which inflammation is a feature. The biggest and most intriguing challenge for the future is therefore to understand whether and where selective A(3) agonists or antagonists are the best choice. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 140
页数:18
相关论文
共 194 条
[41]   An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB [J].
Fishman, P ;
Bar-Yehuda, S ;
Ohana, G ;
Barer, F ;
Ochaion, A ;
Erlanger, A ;
Madi, L .
ONCOGENE, 2004, 23 (14) :2465-2471
[42]  
Fishman P, 1998, CANCER RES, V58, P3181
[43]  
Fishman P, 2003, ANTICANCER RES, V23, P2077
[44]   A3 adenosine receptor as a target for cancer therapy [J].
Fishman, P ;
Bar-Yehuda, S ;
Madi, L ;
Cohn, I .
ANTI-CANCER DRUGS, 2002, 13 (05) :437-443
[45]   Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor [J].
Fishman, P ;
Bar-Yehuda, S ;
Ohana, G ;
Pathak, S ;
Wasserman, L ;
Barer, F ;
Multani, AS .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1452-1458
[46]   Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells [J].
Fossetta, J ;
Jackson, J ;
Deno, G ;
Fan, XD ;
Du, XXK ;
Bober, L ;
Soudé-Bermejo, A ;
de Bouteiller, O ;
Caux, C ;
Lunn, C ;
Lundell, D ;
Palmer, RK .
MOLECULAR PHARMACOLOGY, 2003, 63 (02) :342-350
[47]   ADENOSINE-A(3) RECEPTORS MEDIATE HYPOTENSION IN THE ANGIOTENSIN II-SUPPORTED CIRCULATION OF THE PITHED RAT [J].
FOZARD, JR ;
CARRUTHERS, AM .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (01) :3-5
[48]   Mast cell degranulation following adenosine A(3) receptor activation in rats [J].
Fozard, JR ;
Pfannkuche, HJ ;
Schuurman, HJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 298 (03) :293-297
[49]   Adenosine, an endogenous distress signal, modulates tissue damage and repair [J].
Fredholm, B. B. .
CELL DEATH AND DIFFERENTIATION, 2007, 14 (07) :1315-1323
[50]   Adenosine receptors as targets for drug development [J].
Fredholm, BB .
DRUG NEWS & PERSPECTIVES, 2003, 16 (05) :283-289